'

Predictive toxicology advances through stem cells

Понравилась презентация – покажи это...





Слайд 0

Applications of human stem cell derived cardiomyocytes for predictive toxicology Predictive toxicology advances through stem cells


Слайд 1

Drug development & cardiotoxicity Need for earlier toxicity testing and improved prediction businessreview webinar | 19 March 2014 2 Data from: Wilke et al. Nature Reviews Drug Discovery (2007) 6:904-916


Слайд 2

Predicting drug toxicity Where can we do better? businessreview webinar | 19 March 2014 3


Слайд 3

Human stem cell derived models A way forward for more predictive toxicity testing businessreview webinar | 19 March 2014 4 Self-renewing Scalable Pluripotent Reproducible Convenient


Слайд 4

Stem cell derived human heart cells Industrial production of cardiomyocytes (CytivaTM Plus) businessreview webinar | 19 March 2014 5


Слайд 5

CytivaTM Plus Cardiomyocytes Differentiated human cells for safety & efficacy testing businessreview webinar | 19 March 2014 6 DNA Troponin I a-Actinin Spontaneous contractility


Слайд 6

Electrophysiology hERG block Na+ & Ca2+ channels QT prolongation contractility Cardiomyocytes in drug safety testing Integrated surveillance across platforms & assays businessreview webinar | 19 March 2014 7 Patch Clamp Impedance High Content Imaging Respiration Biochemical Analysis Functional Integrity mitochondrial function membrane integrity Ca2+ homeostasis morphology


Слайд 7

Assessing effects in context Cardiac action potential reflects net ion channel function businessreview webinar | 19 March 2014 8 Planar patch clamp Voltage clamped whole cell currents Verapamil


Слайд 8

Assessing pro-arrhythmic potential Whole cell patch clamp to assess cardiac AP modulation businessreview webinar | 19 March 2014 9 Terfenadine Antihistamine Cisapride GI motility AP Prolongation 3 – 100 nM AP Prolongation 3 – 30 nM EAD 100nM Verapamil Arrhythmia Mixed effects IKr and ICa,L Safe in clinical use


Слайд 9

Comparative pharmacology Species variation in sensitivity of model systems businessreview webinar | 19 March 2014 10 Relative Sensitivity Positive response defined as a change in APD90 >10% Peng, S. et.al., Journal of Pharmacological and Toxicological Methods 61 (2010) 277–286


Слайд 10

Increasing throughput of electrophysiological tests businessreview webinar | 19 March 2014 11 Higher throughput Multi-well formats >> screening ‘ECG-like’ traces, data-rich FPD (“QT”), beat rate, amplitude & slope, conduction velocity, etc. Non-disruptive label-free recording Preserves cell function and cellular connectivity. Chronic vs. acute effects Multiple recording sites in parallel Action potential propagation Ease of use Less skill required compared to manual patch clamp Monolayer culture High success rate Spontaneous & Consistent beat rate Expected shape & pharmacology Multi-Electrode Arrays (MEA) Cardiomyocyte requirements


Слайд 11

FPD (‘QT’) prolongation & contractility Effect of quinidine assessed by multi-electrode arrays businessreview webinar | 19 March 2014 12 [Quinidine] 0.0 mM 0.3 mM 1.0 mM 3.0 mM FPD (“QT”) Prolongation Contractility Changes Q T


Слайд 12

Electrophysiology hERG block Na+ & Ca2+ channels QT prolongation contractility Cardiomyocytes in drug safety testing Integrated surveillance across platforms & assays businessreview webinar | 19 March 2014 13 Patch Clamp Impedance High Content Imaging Respiration Biochemical Analysis 25% Functional Integrity mitochondria plasma membrane intracellular calcium morphology


Слайд 13

Functional integrity High Content Analysis (HCA) businessreview webinar | 19 March 2014 14 Membrane Integrity Dissipation of gradients, organelle disruption, loss of homeostasis Biochemical Integrity Disruption of signal transduction, synthesis, metabolism, cytoskeletal machinery 75%


Слайд 14

High Content Analysis (HCA) & screening businessreview webinar | 19 March 2014 15 Extracting and interpreting multi-parameter data obtained from high-throughput sub-cellular imaging [cells + sensors] [images + data] [information + knowledge]


Слайд 15

Why choose High Content Analysis? Cellular detail extracted rapidly in situ and in context businessreview webinar | 19 March 2014 16


Слайд 16

High content analysis solutions Automated microscopy and analysis for high throughput, high content cell imaging businessreview webinar | 19 March 2014 17 IN Cell Analyzer 2200 Faster, Brighter, Better IN Cell Analyzer 6000 Cell analysis redefined Flexible modular wide field imaging On-board image restoration 7-wavelength solid state illumination Scientific grade CMOS camera Laser based confocal imaging Iris variable aperture technology 405, 488, 561 & 642 nm laser illumination Scientific grade CMOS camera


Слайд 17

CytivaTM HCA kits: cell health & integrity Live interrogation of multiple cell health markers businessreview webinar | 19 March 2014 18


Слайд 18

Cardiotoxic potential of selective kinase inhibitors Using stem cell derived cardiomyocytes & High Content Analysis (HCA) businessreview webinar | 19 March 2014 19 In collaboration with Hirdesh Uppal Ariel Kauss


Слайд 19

Cancer & cardiotoxicity Tyrosine kinase inhibitors 20 Data from: Orphanos G.S. et.al. Cardiotoxicity induced by tyrosine kinase inhibitors 2009; Acta Oncologica, 48: 964-970


Слайд 20

Cardiotoxicity of anticancer drugs Overlapping cardiac signalling & oncology targets 21 Hypertrophic Stimuli Physiological Stimuli Energy Stress Growth Factors Cell Proliferation Hypertrophy Autophagy Cell Death AKT GSK3 ERK RAS RAF AKT BAD AKT LKB AMPK Pathological Stimuli [Ca2+] PLK JNK GSK3 NFAT RTK RTK PI3K PI3K mTOR MEK1 Adapted from; Force T & Kolaja K.L. Nature Reviews Drug Discovery (2011) 10, 111-126


Слайд 21

Cardiotoxicity study compounds Panel of 134 compounds, kinase inhibitor focus, range of classes businessreview webinar | 19 March 2014 22 Nifedipine Neg Control Amiodarone Pos Control


Слайд 22

Cardiotoxicity screen workflow High content analysis (HCA) 384-well format, 7-point dose curves 24h, 48h, 72h time points n=3 wells per treatment condition, 4 images per well businessreview webinar | 19 March 2014 23 Cells Imaging Image Analysis Data Analysis Compounds Fluorescent probes


Слайд 23

Data analysis & interpretation Multi-parameter high content data businessreview webinar | 19 March 2014 24 Pharmacodynamics Phenotypic profiling


Слайд 24

PD 325901 (MEK1) D [Ca2+] only businessreview webinar | 19 March 2014 25


Слайд 25

Entinostat (HDAC) Mitochondrial count and D [Ca2+] businessreview webinar | 19 March 2014 26


Слайд 26

Imatinib/Gleevec (TK) Mitochondrial count & morphology, D [Ca2+], viability businessreview webinar | 19 March 2014 27


Слайд 27

Profile clustering Self organizing maps businessreview webinar | 19 March 2014 28


Слайд 28

Clustering results businessreview webinar | 19 March 2014 See tutorial regarding confidentiality disclosures. 29 *


Слайд 29

Stem cell models in toxicology businessreview webinar | 19 March 2014 30 Stem cell technology offers a way forward for abundant and reproducible supply of human cell models Assessing drug effects in electrophysiological context may reduce likelihood of false negative & positive results hESC-Cardiomyocytes (CytivaTM Plus) provide a relevant model for integrated cardiotoxicity assessment Complementary high content imaging approaches yield mechanistic insights that aid informed decision making


Слайд 30

Stem cell models in toxicology Vision for future development businessreview webinar | 19 March 2014 31 Connectivity in cell models Integration of interrogation methods Comprehensive liability surveillance


Слайд 31

Learn more at the Drug Discovery Knowledge Center The Drug Discovery Knowledge Center gives you access to a wide variety of information to help you achieve deeper insights at every stage of drug discovery from target identification to lead optimization


Слайд 32

CytivaTM Cardiomyocytes are sold under licence from Geron Corporation and Wisconsin Alumni Research Foundation under US patent and publication numbers : US 7,425,448, US 2009/0017465, US 6,800,480, US 5,843,780, US 6,200,806, US 7,029,913, US 7,582,479, US 7,413,902, US 7,297,539, US 2009/0047739 and US 2007/0010012 and equivalent patent and patent applications in other countries. The IN Cell Analyzer system and the IN Cell Investigator software are sold under use license from Cellomics Inc. under US patent numbers US 5989835, 6365367, 6416959, 6573039, 6620591, 6671624, 6716588, 6727071, 6759206, 6875578, 6902883, 6917884, 6970789, 6986993, 7060445, 7085765, 7117098, 7160687, 7235373, 7476510 ; Canadian patent numbers CA 2282658, 2328194, 2362117, 2381344; Australian patent number AU 730100; European patent numbers EP 0983498, 1095277, 1155304, 1203214, 1348124, 1368689; Japanese patent numbers JP 3466568, 3576491, 3683591, 4011936 and equivalent patents and patent applications in other countries. Notice to purchaser: Important license information. © 2014 General Electric Company – All rights reserved. www.gelifesciences.com, GE Healthcare UK Limited. Amersham Place, Little Chalfont, Buckinghamshire, HP7 9NA UK Presented as a businessreview webinar, Predictive toxicology advances through stem cells, 19 March 2014. Thank You !


×

HTML:





Ссылка: